替雷利珠单抗致免疫相关性糖尿病：病例报道与机制探讨，为临床用药敲响警钟！

Tislelizumab is an anti-PD-1 immune checkpoint inhibitor that is widely used in the immunotherapy of various tumors. It may cause immune-related adverse reactions. Immune-related diabetes is one of the rare but serious complications, with rapid and irreversible onset, and is often accompanied by acute attacks of diabetic ketoacidosis. This article reports a case of immune-related diabetes caused by tislelizumab injection. By analyzing the existing literature and clinical cases, the clinical characteristics of immune-related diabetes caused by tislelizumab are summarized, and the mechanism and management of adverse reactions of diabetes caused by immune checkpoint inhibitors and pharmaceutical care are discussed, in order to be vigilant against immune-related diabetes caused by anti-PD-1 immune checkpoint inhibitors in clinical use. ######[AI写代码神器 | 150点数解答 | 2024-10-11 14:59:37]